[Remote] Director, Value, Evidence & Outcomes Liaison (VEOL) – Northeast & East Central at Arcellx

Remote

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Not specified in the provided job description

Responsibilities

Deliver and utilize clinical, value, and outcomes evidence including observational research, comparative effectiveness, and economic data to address customer needs
Synthesize, communicate, and translate complex information packages and/or data into transparent, relevant, objective and actionable insights for value-based decision makers
Collaborate with PHDMs within an assigned geographic "healthcare ecosystem" to understand and address their information needs
Develop and execute the RWE/HEOR strategy collaborating with internal and field-based medical and commercial partners to deliver outstanding customer experiences
Share expertise with customers as their trusted resource on topics related to disease state, Arcellx and competitor products, health outcomes research, quality measures, healthcare policy, technology assessment, economic dynamics, and real-world evidence
Establish valued relationships with PHDMs within assigned accounts at the hospital and payer level
Build and maintain understanding of access landscape, including P&T formulary inclusion, pathway development, payer medical policy coverage, and emerging competitive trends
Collaborate with relevant internal stakeholders to incorporate access insights into account planning

Skills

Key technologies and capabilities for this role

Health Economic ResearchReal-World EvidenceValue ResearchPatient AccessStakeholder EngagementPolicy AnalysisCommunicationCollaboration

Questions & Answers

Common questions about this position

What is the salary or compensation for the Director, Value, Evidence & Outcomes Liaison role?

This information is not specified in the job description.

Is this Director, VEOL position remote or does it require working from an office?

The job involves working from Arcellx's offices in Rockville, Maryland, and Redwood City, California, with no mention of remote work options.

What key skills are required for the VEOL role?

The role requires skills in delivering clinical, value, and outcomes evidence including observational research, comparative effectiveness, and economic data, as well as synthesizing, communicating, and translating complex information into actionable insights for population-based decision makers.

What is the company culture like at Arcellx?

Arcellx fosters a fun, diverse, supportive, and informal environment that is high-performing, inclusive, and collaborative, with core values of authenticity, prioritizing collective success, and embracing challenges.

What makes a strong candidate for this VEOL position?

Strong candidates demonstrate alignment with Arcellx's core values, bring diverse backgrounds and viewpoints, and have expertise in health economics, outcomes research, and engaging with payers and health systems.

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free